New study suggests fish consumption may increase risk of diabetes
NEW YORK Although the benefits of eating fish may lower one’s risk for developing heart disease, one study is suggesting the same does not apply to diabetes.
The study, published in the Septemeber issue of the American Journal of Clinical Nutrition, investigated the relationship between fish and omega-3 fatty acid intake and the development of diabetes among 152,700 women enrolled in the Nurses’ Health Study and 42,504 men enrolled in the Health Professionals Follow-Up Study.
The prevalence of diabetes among the study subjects was 1.17 times more likely among people who ate fish two to four times a week, and 1.22 times more likely among those who ate fish 5 or more times a week, relative to those who ate lesser amounts of fish.
The study was lead by Dr. Frank B. Hu, at Harvard School of Public Health in Boston. Hu and colleagues noted that studies have demonstrated beneficial effects of fish and omega-3 fatty acids on multiple risk factors associated with diabetes, and on heart disease.
Abbott reports Q3 results
ABBOTT PARK, Ill. Drug maker Abbott reported strong sales in its third-quarter 2009 earnings report Wednesday.
The company reported an increase of 8.4% in global sales, which remained at 3.5% when factoring in the rise in the value of the dollar. Excluding the dollar’s rise, pharmaceutical sales were 3.9%, but dipped into the red, to -1.6%, when including foreign exchange rates. Nutritional and medical products had much stronger sales – 11.1% and 9.8%, respectively – when the dollar’s value was included.
“Abbott is performing well, generating higher-than-expected earnings growth in the fourth quarter,” Abbott chairman and CEO Miles White said in a statement. “During the quarter, we announced several acquisitions that support our long-term growth strategy. These acquisitions add to our diverse mix of global businesses, with new technologies, established products and emerging market infrastructure that will help us deliver sustainable industry-leading growth.”
Mylan, Pfizer settle drug dispute
PITTSBURGH Generic drug manufacturer Mylan and pharmaceutical giant Pfizer have settled a dispute over Mylan’s attempt to manufacture a generic version of an antifungal drug.
Mylan announced Wednesday that it had entered a license agreement with Pfizer concerning Mylan subsidiary Matrix Labs’ voriconazole tablets in the 50-mg and 200-mg strengths, a generic version of Pfizer’s Vfend. Matrix had filed a regulatory approval application with the Food and Drug Administration; as the first company to file the application, Mylan will have the right to market its version in direct competition with Pfizer’s product for six months once the patent expires. Under the agreement, Mylan will have the right to market voriconazole tablets in the U.S. in first quarter 2011.
Vfend, used to treat yeast and other fungal infections, had sales of $164 million during the 12-month period ending June 30, according to IMS Health data.